Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas.
Anti-angiogenic agents targeting brain tumor neovasculature may increase progression-free survival in patients with recurrent malignant gliomas. However, when these patients do recur it is not always apparent as an increase in enhancing tumor volume on MRI, which has been the standard of practice for following patients with brain tumors. Therefore alternative methods are needed to evaluate patients treated with these novel therapies. Furthermore, a method that can also provide useful information for the evaluation of conventional therapies would provide an important advantage for general applicability. Diffusion-weighted magnetic resonance imaging (DWI) has the potential to serve as a valuable biomarker for these purposes. In the current study, we explore the prognostic ability of functional diffusion maps (fDMs), which examine voxel-wise changes in the apparent diffusion coefficient (ADC) over time, applied to regions of fluid-attenuated inversion recovery (FLAIR) abnormalities in patients with malignant glioma, treated with either anti-angiogenic or cytotoxic therapies. Results indicate that the rate of change in fDMs is an early predictor of tumor progression, time to progression and overall survival for both treatments, suggesting the application of fDMs in FLAIR abnormal regions may be a significant advance in brain tumor biomarker technology.
Ellingson
Benjamin M
BM
Translational Brain Tumor Research Program, Medical College of Wisconsin, Milwaukee, WI, USA. bellingson@mednet.ucla.edu
Malkin
Mark G
MG
Rand
Scott D
SD
LaViolette
Pete S
PS
Connelly
Jennifer M
JM
Mueller
Wade M
WM
Schmainda
Kathleen M
KM
D001932:Brain Neoplasms / Q000098:blood supply / Q000175:diagnosis* / Q000628:therapy*; D038524:Diffusion Magnetic Resonance Imaging; D018450:Disease Progression; D005910:Glioma / Q000098:blood supply / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000175:diagnosis* / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate; D047368:Tumor Burden
Ann Biomed Eng. 1993 Jul-Aug;21(4):367-75
8214821
Radiology. 1984 Jul;152(1):71-7
6729138
Acta Neurochir Suppl (Wien). 1994;60:413-5
7976605
Neuroimage. 2008 Oct 15;43(1):29-35
18672074
J Neurooncol. 2009 Feb;91(3):329-36
18953493
Clin Cancer Res. 1997 Sep;3(9):1457-66
9815831
Clin Cancer Res. 2007 Feb 15;13(4):1253-9
17317837
J Clin Oncol. 2008 Jul 10;26(20):3387-94
18541899
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64
16267128
Neoplasia. 2009 Feb;11(2):102-25
19186405
AJR Am J Roentgenol. 2001 Aug;177(2):449-54
11461881
Cancer. 1984 May 1;53(9):2002-7
6704925
Eur Radiol. 2000;10(5):745-52
10823626
Neurology. 2009 Oct 13;73(15):1200-6
19822869
J Clin Oncol. 1990 Jul;8(7):1277-80
2358840
J Neurosci Methods. 2005 Mar 15;142(1):67-76
15652618
Neurology. 2002 Sep 24;59(6):947-9
12297589
Cancer. 1997 Sep 1;80(5):936-41
9307194
Surg Neurol. 1998 Apr;49(4):436-40
9537664
AJNR Am J Neuroradiol. 2001 Jun-Jul;22(6):1081-8
11415902
Semin Oncol. 1994 Apr;21(2):162-71
8153662
Magn Reson Med. 1999 Dec;42(6):1014-8
10571921
J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36
11121466
Acta Neurochir (Wien). 2004 Aug;146(8):841-5
15254806
J Magn Reson Imaging. 1999 Jan;9(1):53-60
10030650
J Magn Reson Imaging. 1998 Jul-Aug;8(4):789-98
9702879
Radiol Med. 2008 Mar;113(2):199-213
18386122
AJNR Am J Neuroradiol. 1996 Jun-Jul;17(6):1081-6
8791919
J Magn Reson Imaging. 2010 Mar;31(3):538-48
20187195
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9
15805192
AJNR Am J Neuroradiol. 2006 Aug;27(7):1419-25
16908550
Neoplasia. 2006 Apr;8(4):259-67
16756718
Neurology. 2009 Apr 7;72(14):1217-22
19349600
Radiology. 2009 Jul;252(1):182-9
19561256
Neurology. 2008 Mar 4;70(10):779-87
18316689
J Neurooncol. 2010 May;97(3):419-23
19813078
Magn Reson Med. 2000 Jun;43(6):828-36
10861877